Dynavax to Present at William Blair's 45th Annual Growth Stock Conference

Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, announced its upcoming presentation at William Blair's 45th Annual Growth Stock Conference on June 3rd at 2:40 p.m. CT.

Rhea-AI Summary

Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, announced its upcoming presentation at William Blair's 45th Annual Growth Stock Conference on June 3rd at 2:40 p.m. CT. The presentation will be accessible via webcast through the company's investor relations website.

Dynavax currently markets two commercial products: HEPLISAV-B® vaccine, approved in the U.S., EU, and UK for hepatitis B virus prevention in adults 18 and older, and CpG 1018® adjuvant, which is used in HEPLISAV-B and various COVID-19 vaccines.

Argus Session date unavailable

+2.74% session move Open Argus

Details

News Market Reaction – DVAX

The recorded move for DVAX in the trading session of this news was +2.74%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., May 28, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at William Blair's 45th Annual Growth Stock Conference on Tuesday, June 3rd at 2:40 p.m. CT.

The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com.

For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499

Nicole Arndt
narndt@dynavax.com
510-665-7264

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-william-blairs-45th-annual-growth-stock-conference-302467588.html

SOURCE Dynavax Technologies

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Dynavax (DVAX) presenting at William Blair's Growth Stock Conference?

Dynavax will present at William Blair's 45th Annual Growth Stock Conference on Tuesday, June 3rd at 2:40 p.m. CT.

What are Dynavax's (DVAX) main commercial products?

Dynavax has two main commercial products: HEPLISAV-B vaccine for hepatitis B prevention and CpG 1018 adjuvant used in HEPLISAV-B and COVID-19 vaccines.

Where is HEPLISAV-B vaccine approved for use?

HEPLISAV-B is approved in the United States, the European Union, and the United Kingdom for adults 18 years and older.

How can investors access Dynavax's (DVAX) conference presentation?

Investors can access the webcast through the 'Events & Presentations' page in the 'Investors' section of Dynavax's website at investors.dynavax.com/events-presentations.